

Financial Tear Sheet


Aduro is a clinical-stage cancer immunotherapy company with three products currently in human trials. The company's lead candidate – an immunotherapy regimen combining our proprietary CRS-207 with GVAX Pancreas – is targeting metastatic pancreatic cancer and has received Breakthrough Therapy designation from the US Food and Drug Administration.

Stock Quote

ADRO (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$10.75
Change (%)	- 0.35 (3.15%)
Volume	301,795

Data as of August 18, 2017 4:00 p.m. ET
 Minimum 20 minute delay
[Refresh quote](#)

Stock Chart



Press Releases

August 09, 2017

Aduro Biotech Bolsters Intellectual Property Position in STING Field with Two New Patents

August 03, 2017

Aduro Biotech to Present at the 37th Annual Canaccord Genuity Growth Conference

Events & Presentations

There are currently no events scheduled.

Data Provided by Thomson Reuters